<p>比尔·彼得斯</p>
<p>加拿大生产商 Tilray 和 Canopy Growth 的股票上涨了两位数的涨幅</p>
<p>Tilray 的股票在周二上涨了大约 19%。</p>
<p>在美国总统唐纳德·特朗普前一天表示他 “非常强烈” 考虑签署行政命令重新分类大麻后，美国和加拿大的大麻股票在周二继续上涨，这一举措可能会放宽对该物质的一些监管。</p>
<p>在多个美国州生产大麻的 Curaleaf Holdings (CURLF) 和 Trulieve Cannabis (CA:TRUL) 分别上涨了 8% 和 6.4%。加拿大生产商 Tilray Brands (TLRY) 上涨了 19%，而 Canopy Growth (CGC) 上涨了 11.5%。</p>
<p>特朗普在周一表示，他正在考虑重新分类，因为 “很多人希望看到这一点”，并补充说 “这会导致大量的研究，除非重新分类，否则无法进行。因此我们对此非常重视。”</p>
<p>CNN 在周一报道，白宫一直在讨论将大麻从第一类药物重新分类为第三类药物，并表示可能会在本周宣布这一潜在举措。然而，CNN 表示，尚未就此事达成最终决定。</p>
<p>毒品执法局将第三类药物定义为 “具有中等到低潜在身体和心理依赖性” 的药物。该机构表示，它们的 “滥用潜力低于第一类和第二类药物”。第三类药物的例子包括氯胺酮、合成类固醇、睾酮以及每剂含有少于 90 毫克可待因的产品，如含可待因的泰诺。</p>
<p>在八月，特朗普表示他的政府正在 “考虑重新分类” 大麻。上周，《华盛顿邮报》还报道特朗普将使用行政命令 “简化” 对大麻的获取，消息传出后大麻股票上涨。然而，《邮报》指出，这一举措并不会使大麻合法化或非刑事化。</p>
<p>投资者长期以来一直期待联邦对大麻限制的放松，因为越来越多的美国州将大麻合法化用于娱乐和医疗用途，加拿大企业也在寻求更稳固的途径进入更大的美国市场。然而，近年来联邦立法以合法化或非刑事化该药物的努力停滞不前。</p>
<p>在加拿大于 2018 年合法化娱乐性大麻使用后，那里获得许可的生产商过度扩张并亏损。在缺乏联邦合法化的情况下，一些在大麻合法的美国州的种植者不得不收缩或重新考虑他们的增长目标。</p>
<p>-比尔·彼得斯</p>
<p>此内容由 MarketWatch 创建，MarketWatch 由道琼斯公司运营。MarketWatch 与道琼斯新闻通讯和《华尔街日报》独立出版。</p>
<p>（完）道琼斯新闻通讯</p>
<p>12-16-25 1206ET</p>

TLRY

<p>在特朗普总统宣布他 “非常强烈” 考虑重新分类大麻后，大麻股票大幅上涨，这可能会放宽监管。这一举措可能将大麻从第一类药物重新分类为第三类药物，从而允许更多的研究。Tilray 和 Canopy Growth 等股票获得了显著的涨幅。白宫正在讨论这一重新分类，但尚未做出最终决定。尽管过去的立法进展缓慢，投资者对联邦放宽监管的前景充满希望，因为越来越多的美国州已经合法化大麻</p>

<p>By Bill Peters</p>
<div class="lb-trans"><p>比尔·彼得斯</p>
</div><p>Shares of Canadian producers Tilray and Canopy Growth put up double-digit gains</p>
<div class="lb-trans"><p>加拿大生产商 Tilray 和 Canopy Growth 的股票上涨了两位数的涨幅</p>
</div><p>Shares of Tilray jumped roughly 19% on Tuesday.</p>
<div class="lb-trans"><p>Tilray 的股票在周二上涨了大约 19%。</p>
</div><p>Shares of U.S. and Canadian cannabis stocks continued their rally on Tuesday, after President Donald Trump a day earlier said he was &#34;very strongly&#34; weighing an executive order to reschedule the drug, a move that could lift some regulations on the substance.</p>
<div class="lb-trans"><p>在美国总统唐纳德·特朗普前一天表示他 “非常强烈” 考虑签署行政命令重新分类大麻后，美国和加拿大的大麻股票在周二继续上涨，这一举措可能会放宽对该物质的一些监管。</p>
</div><p>Curaleaf Holdings (CURLF) and Trulieve Cannabis (CA:TRUL), which produce cannabis in multiple U.S states, were up 8% and 6.4%, respectively. Canadian producer Tilray Brands (TLRY) jumped 19%, while Canopy Growth (CGC) moved 11.5% higher.</p>
<div class="lb-trans"><p>在多个美国州生产大麻的 Curaleaf Holdings (CURLF) 和 Trulieve Cannabis (CA:TRUL) 分别上涨了 8% 和 6.4%。加拿大生产商 Tilray Brands (TLRY) 上涨了 19%，而 Canopy Growth (CGC) 上涨了 11.5%。</p>
</div><p>Trump on Monday said he was considering reclassification because &#34;a lot of people want to see it,&#34; adding that &#34;it leads to tremendous amounts of research that can't be done unless you reclassify. So we are looking at that very strongly.&#34;</p>
<div class="lb-trans"><p>特朗普在周一表示，他正在考虑重新分类，因为 “很多人希望看到这一点”，并补充说 “这会导致大量的研究，除非重新分类，否则无法进行。因此我们对此非常重视。”</p>
</div><p>CNN reported on Monday that the White House has been discussing recategorizing cannabis from Schedule I to a Schedule III substance, and said an announcement on a potential move could come this week. However, CNN said, no decision on the matter had been finalized.</p>
<div class="lb-trans"><p>CNN 在周一报道，白宫一直在讨论将大麻从第一类药物重新分类为第三类药物，并表示可能会在本周宣布这一潜在举措。然而，CNN 表示，尚未就此事达成最终决定。</p>
</div><p>The Drug Enforcement Administration defines Schedule III drugs as those &#34;with a moderate to low potential for physical and psychological dependence.&#34; The agency says their &#34;abuse potential is less than Schedule I and Schedule II drugs.&#34; Examples of Schedule III drugs include ketamine, anabolic steroids, testosterone and products with under 90 milligrams of codeine per dose, like Tylenol with codeine.</p>
<div class="lb-trans"><p>毒品执法局将第三类药物定义为 “具有中等到低潜在身体和心理依赖性” 的药物。该机构表示，它们的 “滥用潜力低于第一类和第二类药物”。第三类药物的例子包括氯胺酮、合成类固醇、睾酮以及每剂含有少于 90 毫克可待因的产品，如含可待因的泰诺。</p>
</div><p>In August, Trump said his administration was &#34;looking at reclassification&#34; of cannabis. Last week, the Washington Post also reported that Trump would use an executive order to &#34;ease access&#34; to cannabis, and pot stocks jumped on the news. However, the Post noted that such a move would not legalize or decriminalize cannabis.</p>
<div class="lb-trans"><p>在八月，特朗普表示他的政府正在 “考虑重新分类” 大麻。上周，《华盛顿邮报》还报道特朗普将使用行政命令 “简化” 对大麻的获取，消息传出后大麻股票上涨。然而，《邮报》指出，这一举措并不会使大麻合法化或非刑事化。</p>
</div><p>Investors in cannabis stocks have long awaited the loosening of federal restrictions on cannabis, as more U.S. states legalize pot for recreational and medical use and as Canadian players seek a firmer pathway into a far bigger U.S. market. However, federal legislation in recent years to legalize or decriminalize the drug has stalled.</p>
<div class="lb-trans"><p>投资者长期以来一直期待联邦对大麻限制的放松，因为越来越多的美国州将大麻合法化用于娱乐和医疗用途，加拿大企业也在寻求更稳固的途径进入更大的美国市场。然而，近年来联邦立法以合法化或非刑事化该药物的努力停滞不前。</p>
</div><p>After Canada legalized recreational cannabis use in 2018, licensed producers there overexpanded and lost money. In the absence of federal legalization, some cannabis growers in U.S. states where the drug is legal have had to retrench or otherwise rethink their ambitions for growth.</p>
<div class="lb-trans"><p>在加拿大于 2018 年合法化娱乐性大麻使用后，那里获得许可的生产商过度扩张并亏损。在缺乏联邦合法化的情况下，一些在大麻合法的美国州的种植者不得不收缩或重新考虑他们的增长目标。</p>
</div><p>-Bill Peters</p>
<div class="lb-trans"><p>-比尔·彼得斯</p>
</div><p>This content was created by MarketWatch, which is operated by Dow Jones &amp; Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.</p>
<div class="lb-trans"><p>此内容由 MarketWatch 创建，MarketWatch 由道琼斯公司运营。MarketWatch 与道琼斯新闻通讯和《华尔街日报》独立出版。</p>
</div><p>(END) Dow Jones Newswires</p>
<div class="lb-trans"><p>（完）道琼斯新闻通讯</p>
</div><p>12-16-25 1206ET</p>
<div class="lb-trans"><p>12-16-25 1206ET</p>
</div>

大麻股票持续火热上涨，特朗普表示他正在 ‘非常认真地’ 考虑重新调整大麻的分类